<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538575</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00387-42</org_study_id>
    <nct_id>NCT02538575</nct_id>
  </id_info>
  <brief_title>6 Minute Walk Test in Cystic Fibrosis</brief_title>
  <acronym>MUCO-TM6</acronym>
  <official_title>Prognosis Contribution of the 6 Minute Walk Test in Cystic Fibrosis : Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Data analysis : EFFI-STAT (statistic expert)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Methodologist : URC-CIC-Paris Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Funding : Association Vaincre La Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the 6-minute walk test (6MWT) could be a
      prognostic factor for cystic fibrosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 6-minute walk test is a simple exercise test, reproducing a daily physical activity. The
      utility of this test is described in several chronic lung diseases (chronic obstructive
      pulmonary disease, idiopathic pulmonary arterial hypertension). The distance performed during
      the 6MWT and / or desaturation during the 6MWT is a prognostic factor that contributes to the
      assessment of patients for lung transplantation indication.

      The 6MWT is practiced routinely in cystic fibrosis centers but its usefulness in this disease
      has not been shown. Also the results of this test are not part of the decision-making
      criteria for lung transplantation.

      A single-center study performed in adults CRCM at Cochin Hospital suggests the prognostic
      value of the 6MWT in patients with adult's cystic fibrosis.

      The principal objective of this study is to assess the prognostic of 6MWT as part of the
      cystic fibrosis. The primary endpoint will be to assess the survival without lung transplant
      during the follow up period of 3 years. In this context, this prognostic tool could be used
      to help to determine the best time to consider a lung transplant in cystic fibrosis patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without lung transplant</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distance traveled during the 6MWT</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation (SpO2&lt;90%) measured by a plethysmography exam during the 6MWT</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of intravenous antibiotic therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea questionnaire (mMRC scale)</measure>
    <time_frame>once a year during 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the Quality of life (Cystic Fibrosis Questionnaire 14+, SF12)</measure>
    <time_frame>once a year during 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Anxiety and Depression (Hospital Anxiety Depression HAD scale)</measure>
    <time_frame>once a year during 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the Physical activity (Baecke questionnaire)</measure>
    <time_frame>once a year during 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>6-minute walk test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>6-minute walk test</intervention_name>
    <description>a walk of 6 minutes repeated twice in an interval of 30 minutes</description>
    <arm_group_label>6-minute walk test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Cystic Fibrosis (bronchiectasis with presence of two mutations in the
             CFTR gene and / or positive sweat test.

          -  Patients aged 18 year or older.

          -  Pre-bronchodilator FEV1 FEV1 ≤ 60% from theoretical value: this FEV1 limits is
             proposed following the results from our published study (Martin et al. 2013) showing
             that desaturation during 6MWT and a distance ≤ 475m performed, are almost exclusively
             found in patients with FEV1 ≤ 60% .

          -  Stable health status ( &gt;15 days after the start of treatment of a respiratory
             exacerbation

          -  No indications against the walking test:

        Left uncontrolled heart failure Severe aortic stenosis acute endocarditis syncope
        Symptomatic severe arrhythmia stable angina Myocardial infarction &lt;5 days Acute respiratory
        distress Resting SpO2≤85% pulmonary edema Uncontrolled asthma Arterial or venous thrombosis
        of the lower limbs, Severe acute condition that may interfere with the exercise performance
        (infections, renal failure, hyperthyroidism, unable to cooperate, severe pulmonary arterial
        hypertension, severe systemic blood pressure (Systolic blood pressure &gt;200 mm Hg and / or
        diastolic blood pressure &gt;120 mm Hg))

        Exclusion Criteria:

          -  History of lung transplant

          -  Oxygen Dependence (inability to achieve a 6-minute walk test in ambient air)

          -  Any indication against walk test

          -  Pregnant women, persons deprived of liberty, person under guardianship, person in
             emergency situation

          -  Person not affiliated to social security system

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Regis BURGEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prissile Bakouboula, PhD</last_name>
    <phone>+33158413478</phone>
    <email>prissile.bakouboula@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Le Guen, Master</last_name>
    <phone>+33144494327</phone>
    <email>sophie.le-guen@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Cochin, service de pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Regis BURGEL, MD, PhD</last_name>
      <phone>+33158412367</phone>
      <email>pierre-regis.burgel@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Regis BURGEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Martin C, Chapron J, Hubert D, Kanaan R, Honoré I, Paillasseur JL, Aubourg F, Dinh-Xuan AT, Dusser D, Fajac I, Burgel PR. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med. 2013 Dec;107(12):1881-7. doi: 10.1016/j.rmed.2013.10.001. Epub 2013 Oct 11.</citation>
    <PMID>24157200</PMID>
  </reference>
  <reference>
    <citation>Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1428-46. doi: 10.1183/09031936.00150314. Epub 2014 Oct 30. Review.</citation>
    <PMID>25359355</PMID>
  </reference>
  <reference>
    <citation>Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, McCormack MC, MacIntyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1447-78. doi: 10.1183/09031936.00150414. Epub 2014 Oct 30. Review.</citation>
    <PMID>25359356</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Adults</keyword>
  <keyword>6-minute walk test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

